Gemma Salvadó

🚨Postdoc position open at @BarcelonaBeta🚨
We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠
Fully funded position!!!
More details: www.imim.cat/media/upload...
Please share!
#Alzheimer's #ENDALZ

Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals.
Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET

Excited to share our review on the latest developments in neuroimaging in #Alzheimer’s disease .

Great resource to be up to date!

New Blood Test Could Personalize Alzheimer's Treatment Like Never Before A new Alzheimer's blood test may reveal how far the disease has progressed and identify who's most likely to benefit from anti-amyloid therapies.

A next-generation blood test could personalize Alzheimer's treatment by revealing disease progression—not just diagnosis.

BrightFocus Foundation grant recipient, Dr. Gemma Salvadó, helped validate this test to identify ideal candidates for anti-amyloid therapies.

🔬 Full story ⬇️

New paper published today in @nataging.nature.com !
This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data.
A 🧵 below.
#ENDALZ

Super proud of @noellewarmenhoven.bsky.social !
She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦

Today I will present our work titled: Biological staging of AD with the novel plasma eMTBR-tau243 and %p-tau217
🪧Insights into disease trajectory and biological staging of AD (session)
🕑 2PM
📍 Room 105 (even if it's not in the app)
Don't miss it, it will be a great session!
#AAIC2025

Outstanding plenary presentation by @sylviavilleneuve.bsky.social today on preclinical #Alzheimer’s disease. Her comprehensive overview of biomarkers, risk factors, and clinical trials highlighted critical directions for the future of AD research.
#AAIC2025

Powerful words from Cliff Jack as he accepted his lifetime achievement award.
We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer’s.
#AAIC2025

If you're at #AAIC2025, don't miss the great work by @wiesjepelkmans.bsky.social !

What a plenary!
Congratulations @emmacoomans.bsky.social for such a great presentation at #AIC today, summarising the main neuroimaging papers of the year.
Very exciting way to start #AAIC2025 🇨🇦

🚨 Heading to @EANM_NucMed meeting in Barcelona this fall?
Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments.
Join the discussion on what’s next and why it matters
#EANM2025 #Neuroimaging #Alzheimers

Yesterday, @anikawuestefeld.bsky.social brilliantly defended her PhD thesis on the fole of MTL in Alzheimer’s disease.
It was a brilliant discussion with @jmschott.bsky.social between peers.
Congratulations Dr. Wuestefeld! You did a great job👏👏👏

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/

Super excited to announce a PhD position on polypathology in the medial temporal lobe at the Paris Brain Institute together with @nvillain-alz.bsky.social and @robindeflores.bsky.social!

offres.institutducerveau-icm.org/fr/jobs/1935...

Please repost!

Important work from @biofinder.bsky.social and @barcelonabeta.bsky.social groups!

El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre Un análisis de sangre permite diagnosticar la mayoría de casos de alzheimer de manera precoz, cuando los afectados tienen síntomas incipientes de deterioro cognitivo,

🔵🔬El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre. El test ya está a punto para utilizarse de manera rutinaria en los hospitales, y no solo con fines de investigación como hasta ahora.

www.lavanguardia.com/ciencia/2025...

If you're at #ADPD25 you can go to biomarkers, imaging and translational aspects in Hall A for a live presentation by Kanta Horie (14:45 CET)

Proud to be part of this important collaboration with Kanta Horie and Randall Bateman from Washington University in St. Louis and Oskar Hansson from @biofinder.bsky.social among many others!

Huge development towards a precise and scalable diagnosis of #Alzheimer's disease.

Plasma MTBR-tau243 is more strongly associated with aggregated tau pathology and cognitive function than 🩸 p-tau217. Suggesting similar results than tau-PET with significantly lower costs and burden for patients

Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data INTRODUCTION Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost an...

🚨New paper published in @alzdemjournals! doi.org/10.1002/alz.14600

PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇

Incredible plenary presentation by @rikossenkoppele.bsky.social at AAIC Neuroscience Next in Barcelona! Ending on a hopeful note for the future of #Alzheimer's research and therapeutics.

Thrilled to be back home at BBRC & Fundació Pasqual Maragall as the Lead of the Neuroimaging Group! 🎉
Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇
t.co/WPPavUgpjl

APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta Cicognola et al. investigate the relationship between the APOE4 gene—the strongest genetic risk factor for Alzheimer’s disease—and tau. They find that the

A new The Swedish BioFINDER study paper in collaboration with WRAP has been published in
Brain!
academic.oup.com/brain/advanc...
Find our key findings 👇

Such an honour to receive the young investigator award from my favourite conference.
Especially when shared with these amazing researchers!
#HAI2025
I couldn't start this account with better news.

Hi!
Could you also add me to the list, please? I'm an associate researcher at Lund University interested in fluid and imaging biomarkers in AD